BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Sleep Med 2020;75:510-21. [PMID: 33032062 DOI: 10.1016/j.sleep.2020.09.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Abad VC. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nat Sci Sleep 2021;13:75-91. [PMID: 33531850 DOI: 10.2147/NSS.S245020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
2 Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, Gao H, Chen G. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials. Pharmacol Res 2021;167:105522. [PMID: 33667687 DOI: 10.1016/j.phrs.2021.105522] [Reference Citation Analysis]
3 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
4 Fernandes M, Placidi F, Mercuri NB, Liguori C. The Importance of Diagnosing and the Clinical Potential of Treating Obstructive Sleep Apnea to Delay Mild Cognitive Impairment and Alzheimer's Disease: A Special Focus on Cognitive Performance. J Alzheimers Dis Rep 2021;5:515-33. [PMID: 34368635 DOI: 10.3233/ADR-210004] [Reference Citation Analysis]